5

- 15

20

## WHAT IS CLAIMED IS:

- 1. An isolated or recombinant polynucleotide encoding an antigenic polypeptide comprising at least 17 contiguous amino acids from the mature polypeptide from SEO ID NO: 2, 4, 6, or 8.
  - 2. The polynucleotide of Claim 1, encoding a mature polypeptide from SEQ ID NO: 2, 4, 6, or 8.
- The polynucleotide of Claim 1, which hybridizes at 55° C, less than 500 mM salt, and 50% formamide to the coding portions of SEQ ID NO: 1, 3, 5, or 7.
  - 4. The polynucleotide of Claim 3, comprising at least 35 contiguous nucleotides of the coding portion of SEQ ID NO: 1, 3, 5, or 7.
  - 5. An expression vector comprising the polynucleotide of Claim 1.
  - 6. A host cell containing the expression vector of Claim 5, including a eukaryotic cell.
  - 7. A method of making an antigenic polypeptide comprising expressing a recombinant polynucleotide of Claim 1.
- 8. A method for forming a duplex with a polynucleotide of Claim 1,
  25 comprising contacting said polynucleotide with a probe that hybridizes, under stringent conditions, to at least 25 contiguous nucleotides of the coding portion of SEQ ID NO: 1,
  3, 5, or 7; thereby forming said duplex.

15

20

30

- 9. A kit for the detection of a polynucleotide of Claim 1, comprising a polynucleotide that hybridizes, under stringent hybridization conditions, to at least 17 contiguous nucleotides of a polynucleotide of Claim 1.
- 5 10. The kit of claim 9, wherein said probe is detectably labeled.
  - 11. A binding compound comprising an antibody binding site which specifically binds to at least 17 contiguous amino acids from SEQ ID NO: 2, 4, 6, or 8.
- 10 12. The binding compound of Claim 11, wherein:
  - a) said antibody binding site is:
    - 1) specifically immunoreactive with a polypeptide of SEQ ID NO: 2, 4, 6 or 8;
    - 2) raised against a purified or recombinantly produced human IL-D80 or IL-27 protein; or
    - 3) in a monoclonal antibody, Fab, or F(ab)2; or
  - b) said binding compound is:
    - 1) an antibody molecule;
    - 2) a polyclonal antiserum;
    - 3) detectably labeled;
    - 4) sterile; or
    - 5) in a buffered composition.
- 13. A method using the binding compound of Claim 11, comprising
  contacting said binding compound with a biological sample comprising an antigen,
  wherein said contacting results in formation of a binding compound:antigen complex.
  - 14. The method of Claim 13, wherein said biological sample is from a human, and wherein said binding compound is an antibody.
  - 15. A detection kit comprising said binding compound of Claim 12, and:

- a) instructional material for the use of said binding compound for said detection; or
- b) a compartment providing segregation of said binding compound.
- 5 16. A substantially pure or isolated antigenic polypeptide, which binds to said binding composition of Claim 11, and further comprises at least 17 contiguous amino acids from SEQ ID NO: 2, 4, 6, or 8.
  - 17. The polypeptide of Claim 16, which:
- a) comprises at least a fragment of at least 25 contiguous amino acid residues from a primate IL-D80 or IL-27 protein;
  - b) is a soluble polypeptide;
  - c) is detectably labeled;
  - d) is in a sterile composition;
- e) is in a buffered composition;
  - f) binds to a cell surface receptor;
  - g) is recombinantly produced; or
  - h) has a naturally occurring polypeptide sequence.
- 20 18. The polypeptide of Claim 17, which comprises at least 17 contiguous amino acids of SEQ ID NO: 2, 4, 6, or 8.
- 19. A method of modulating physiology or development of a cell or tissue culture cells comprising contacting said cell with an agonist or antagonist of a primate 25 IL-D80 or IL-27.

5

15

- 20. The method of Claim 19, wherein:
  - a) said contacting is in combination with an agonist or antagonist of IL-12; or
  - b) said contacting is with an antagonist, including binding composition comprising an antibody binding site which specifically binds an IL-D80 or IL-27.
- 21. A composite cytokine comprising a plurality of segments of SEQ ID NO: 2, 4, 6, or 8 and SEQ ID NO: 10.
- An isolated or recombinant polynucleotide encoding the composite cytokine of Claim 21.
  - 23. A binding composition which specifically binds to an antigenic fragment of the composite cytokine of Claim 21.
  - A receptor subunit:ligand composition comprising a plurality of polypeptide segments of SEQ ID NO: 2, 4, 6, or 8; SEQ ID NO:10; and SEQ ID NO:12.
- 25. A binding composition which specifically binds to an antigenic fragment of the receptor